SHP2 inhibitors: Recent advancements and potential breakthroughs in cancer therapy
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2022.
Автор: | Meem, Manila |
---|---|
Інші автори: | Akter, Dr. Raushanara |
Формат: | Дисертація |
Мова: | English |
Опубліковано: |
Brac University
2023
|
Предмети: | |
Онлайн доступ: | http://hdl.handle.net/10361/18081 |
Схожі ресурси
-
A review on potential of PARP inhibitors in the treatment of prostate cancer
за авторством: Islam, Saidul
Опубліковано: (2022) -
RIPK pathway, as a potential target, for cancer treatment - a review
за авторством: Jahan, Nusrat
Опубліковано: (2024) -
Efficacy analysis of tyrosine kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer
за авторством: Flora, Sanzida Alam
Опубліковано: (2024) -
Immunotherapy in the Management of Lung Cancer
за авторством: Tasnim, Humayra
Опубліковано: (2022) -
A review of next-generation immuno-oncology agents for cancer therapy: recent dictation shifts in cancer immunotherapy
за авторством: Ratu, Tabassum
Опубліковано: (2024)